New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity.
The first biologically active non-planar analogues of the toxic anti-cancer agent, fascaplysin, have been produced; we present the design, synthesis and biological activity of three tryptamine derivatives.